The cell and gene therapy patient access and reimbursement market is expanding with new insurance frameworks, outcome-based payment schemes, and growing demand for personalized, high-cost treatments. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Gene Therapy Patient Access and Reimbursement Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Gene Therapy Patient Access and Reimbursement Market, by Therapy Type
8.1.1. CAR T Cell Therapies
8.1.1.1. Market Revenue and Forecast
8.1.2. Gene Replacement Therapies (e.g., Luxturna, Zolgensma)
8.1.2.1. Market Revenue and Forecast
8.1.3. Gene-Edited Therapies (e.g., Casgevy – CRISPR for sickle cell)
8.1.3.1. Market Revenue and Forecast
8.1.4. Cell-Based Therapies (e.g., stem cell transplants)
8.1.4.1. Market Revenue and Forecast
8.1.5. RNA-Based Therapies
8.1.5.1. Market Revenue and Forecast
8.1.6. Others (e.g., multigenic, combination platforms)
8.1.6.1. Market Revenue and Forecast
9.1. Cell and Gene Therapy Patient Access and Reimbursement Market, by Reimbursement Model
9.1.1. Traditional Lump-Sum Payment
9.1.1.1. Market Revenue and Forecast
9.1.2. Outcomes-Based Contracts / Value-Based Agreements
9.1.2.1. Market Revenue and Forecast
9.1.3. Annuity/Installment Payment Models
9.1.3.1. Market Revenue and Forecast
9.1.4. Rights & Outcome-Based Refunds
9.1.4.1. Market Revenue and Forecast
9.1.5. Risk-Pooling Funds
9.1.5.1. Market Revenue and Forecast
9.1.6. Others (e.g., population-level budgeting)
9.1.6.1. Market Revenue and Forecast
10.1. Cell and Gene Therapy Patient Access and Reimbursement Market, by Payer Type
10.1.1. Public Payers (e.g., Medicare, Medicaid)
10.1.1.1. Market Revenue and Forecast
10.1.2. Private Insurers
10.1.2.1. Market Revenue and Forecast
10.1.3. Specialty Carve-Out Funds
10.1.3.1. Market Revenue and Forecast
10.1.4. Payer Consortia & Risk Pools
10.1.4.1. Market Revenue and Forecast
10.1.5. Others (e.g., philanthropic funds, hospitals)
10.1.5.1. Market Revenue and Forecast
11.1. Cell and Gene Therapy Patient Access and Reimbursement Market, by Treatment Setting
11.1.1. Hospital Clinics / Specialty Centers
11.1.1.1. Market Revenue and Forecast
11.1.2. Home Infusion (for select gene therapies)
11.1.2.1. Market Revenue and Forecast
11.1.3. Specialty Pharmacies
11.1.3.1. Market Revenue and Forecast
11.1.4. Others (e.g., academic/teaching hospitals)
11.1.4.1. Market Revenue and Forecast
12.1. Cell and Gene Therapy Patient Access and Reimbursement Market, by Patient Demographics
12.1.1. Pediatric
12.1.1.1. Market Revenue and Forecast
12.1.2. Adult
12.1.2.1. Market Revenue and Forecast
12.1.3. Geriatric
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy Type
13.1.2. Market Revenue and Forecast, by Reimbursement Model
13.1.3. Market Revenue and Forecast, by Payer Type
13.1.4. Market Revenue and Forecast, by Treatment Setting
13.1.5. Market Revenue and Forecast, by Patient Demographics
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy Type
13.1.6.2. Market Revenue and Forecast, by Reimbursement Model
13.1.6.3. Market Revenue and Forecast, by Payer Type
13.1.6.4. Market Revenue and Forecast, by Treatment Setting
13.1.6.5. Market Revenue and Forecast, by Patient Demographics
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Therapy Type
13.1.7.2. Market Revenue and Forecast, by Reimbursement Model
13.1.7.3. Market Revenue and Forecast, by Payer Type
13.1.7.4. Market Revenue and Forecast, by Treatment Setting
13.1.7.5. Market Revenue and Forecast, by Patient Demographics
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy Type
13.2.2. Market Revenue and Forecast, by Reimbursement Model
13.2.3. Market Revenue and Forecast, by Payer Type
13.2.4. Market Revenue and Forecast, by Treatment Setting
13.2.5. Market Revenue and Forecast, by Patient Demographics
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy Type
13.2.6.2. Market Revenue and Forecast, by Reimbursement Model
13.2.6.3. Market Revenue and Forecast, by Payer Type
13.2.7. Market Revenue and Forecast, by Treatment Setting
13.2.8. Market Revenue and Forecast, by Patient Demographics
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy Type
13.2.9.2. Market Revenue and Forecast, by Reimbursement Model
13.2.9.3. Market Revenue and Forecast, by Payer Type
13.2.10. Market Revenue and Forecast, by Treatment Setting
13.2.11. Market Revenue and Forecast, by Patient Demographics
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy Type
13.2.12.2. Market Revenue and Forecast, by Reimbursement Model
13.2.12.3. Market Revenue and Forecast, by Payer Type
13.2.12.4. Market Revenue and Forecast, by Treatment Setting
13.2.13. Market Revenue and Forecast, by Patient Demographics
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy Type
13.2.14.2. Market Revenue and Forecast, by Reimbursement Model
13.2.14.3. Market Revenue and Forecast, by Payer Type
13.2.14.4. Market Revenue and Forecast, by Treatment Setting
13.2.15. Market Revenue and Forecast, by Patient Demographics
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy Type
13.3.2. Market Revenue and Forecast, by Reimbursement Model
13.3.3. Market Revenue and Forecast, by Payer Type
13.3.4. Market Revenue and Forecast, by Treatment Setting
13.3.5. Market Revenue and Forecast, by Patient Demographics
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy Type
13.3.6.2. Market Revenue and Forecast, by Reimbursement Model
13.3.6.3. Market Revenue and Forecast, by Payer Type
13.3.6.4. Market Revenue and Forecast, by Treatment Setting
13.3.7. Market Revenue and Forecast, by Patient Demographics
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy Type
13.3.8.2. Market Revenue and Forecast, by Reimbursement Model
13.3.8.3. Market Revenue and Forecast, by Payer Type
13.3.8.4. Market Revenue and Forecast, by Treatment Setting
13.3.9. Market Revenue and Forecast, by Patient Demographics
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy Type
13.3.10.2. Market Revenue and Forecast, by Reimbursement Model
13.3.10.3. Market Revenue and Forecast, by Payer Type
13.3.10.4. Market Revenue and Forecast, by Treatment Setting
13.3.10.5. Market Revenue and Forecast, by Patient Demographics
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy Type
13.3.11.2. Market Revenue and Forecast, by Reimbursement Model
13.3.11.3. Market Revenue and Forecast, by Payer Type
13.3.11.4. Market Revenue and Forecast, by Treatment Setting
13.3.11.5. Market Revenue and Forecast, by Patient Demographics
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy Type
13.4.2. Market Revenue and Forecast, by Reimbursement Model
13.4.3. Market Revenue and Forecast, by Payer Type
13.4.4. Market Revenue and Forecast, by Treatment Setting
13.4.5. Market Revenue and Forecast, by Patient Demographics
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy Type
13.4.6.2. Market Revenue and Forecast, by Reimbursement Model
13.4.6.3. Market Revenue and Forecast, by Payer Type
13.4.6.4. Market Revenue and Forecast, by Treatment Setting
13.4.7. Market Revenue and Forecast, by Patient Demographics
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy Type
13.4.8.2. Market Revenue and Forecast, by Reimbursement Model
13.4.8.3. Market Revenue and Forecast, by Payer Type
13.4.8.4. Market Revenue and Forecast, by Treatment Setting
13.4.9. Market Revenue and Forecast, by Patient Demographics
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy Type
13.4.10.2. Market Revenue and Forecast, by Reimbursement Model
13.4.10.3. Market Revenue and Forecast, by Payer Type
13.4.10.4. Market Revenue and Forecast, by Treatment Setting
13.4.10.5. Market Revenue and Forecast, by Patient Demographics
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy Type
13.4.11.2. Market Revenue and Forecast, by Reimbursement Model
13.4.11.3. Market Revenue and Forecast, by Payer Type
13.4.11.4. Market Revenue and Forecast, by Treatment Setting
13.4.11.5. Market Revenue and Forecast, by Patient Demographics
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy Type
13.5.2. Market Revenue and Forecast, by Reimbursement Model
13.5.3. Market Revenue and Forecast, by Payer Type
13.5.4. Market Revenue and Forecast, by Treatment Setting
13.5.5. Market Revenue and Forecast, by Patient Demographics
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy Type
13.5.6.2. Market Revenue and Forecast, by Reimbursement Model
13.5.6.3. Market Revenue and Forecast, by Payer Type
13.5.6.4. Market Revenue and Forecast, by Treatment Setting
13.5.7. Market Revenue and Forecast, by Patient Demographics
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy Type
13.5.8.2. Market Revenue and Forecast, by Reimbursement Model
13.5.8.3. Market Revenue and Forecast, by Payer Type
13.5.8.4. Market Revenue and Forecast, by Treatment Setting
13.5.8.5. Market Revenue and Forecast, by Patient Demographics
14.1. Novartis AG (Kymriah)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Gilead/Kite (Yescarta, Tecartus)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Spark Therapeutics (Luxturna)
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Bluebird Bio (Zynteglo, Lyfgenia)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Vertex & CRISPR Therapeutics (Casgevy)
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Spark Therapeutics (Luxturna)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Roche / Spark
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Roche / Novartis partnership
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. US CMS (Medicare/Medicaid payers)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Italy’s AIFA
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description